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Uday Popat1Leukemic transformation (LT) from myelofibrosis has a very poor prognosis with the current treatment
strategies. We hypothesized that allogeneic stem cell transplantation (ASCT) can improve outcomes for
patients with LT, and reviewed 55 consecutive patients that were treated for myelofibrosis with ASCT at
our institution. Fourteen patients (25%) were identified to have LT. Thirteen of these patients received in-
duction chemotherapy and 6 achieved remission at the time of transplant. Conditioning regimenwas melpha-
lan (Mel)-based in 9 patients. All patients engrafted and achieved remission after transplant, whereas 4
subsequently relapsed. After a median follow-up of 31months, 6 patients (49%) survived long term. Although
limited by a small number of patients, this study suggests that patients with myelofibrosis and LT may achieve
long-term remission after induction chemotherapy and ASCT.
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Primary myelofibrosis (PMF) is a clonal myeloge-
nous disease of unknownetiology characterized by neo-
plastic megakaryocyte proliferation, extensive bone
marrow (BM)fibrosis,massive splenomegaly,mobiliza-
tion of stem cells in circulation, and extramedullary
hematopoiesis [1-3]. Secondary myelofibrosis (SMF)
is the consequence of progression of polycythemia
vera (PV) or essential thrombocythemia (ET) to a dis-
ease indistinguishable from PMF [4]. The disease
evolves to a phase of extensive tumor burden, progres-
sive cytopenias, followed eventually by a myelogenous
blast phase that resembles acutemyelogenous leukemia
(AML), categorized by theWorldHealthOrganization
(WHO)asmyeloid leukemiaevolving fromamyelopro-
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6/j.bbmt.2009.12.004Leukemic transformation (LT)has adismalprogno-
sis with the current treatment strategies [6]. Allogeneic
stem cell transplantation (ASCT) is a curative approach
for patients with MF [7,8]; however, the outcomes of
patients with LT are currently unknown. Here, we
hypothesized that patients with myelofibrosis and LT
can achieve durable long-term remission after ASCT.PATIENTS AND METHODS
Selection of Patients
Of 55 consecutive patients with myelofibrosis who
received an ASCT at the University of Texas M.D.
Anderson Cancer Center between August 1994 and
November 2008, 14 patients (25%) were identified to
have LT (defined as.20% blasts in the BM or periph-
eral blood [PB]]). Patients with myelofibrosis and
\20% blasts and patients with other myeloprolifera-
tive diseases transformed to AML were not included
in this study. A retrospective study protocol, which in-
cluded a waiver of informed consent, was approved by
theM.D. Anderson Cancer Center institutional review
board.
Characteristics of these patients are presented in
Table 1. Thirteen patients received induction chemo-
therapy for LT, 8 with ‘‘317’’ regimen (idarubicin or
daunorubicin plus cytarabine), 3 with cytarabine and
either fludarabine (Flu) or azacytidine, and 2 with
other agents. Six patients achieved complete remission
(CR), 6 had a reduction in the percentage of BM blasts555
Table 1. Patient Characteristics
Number of patients 14
Age (median, range) 59 (50-67)
Sex
Male 9
Diagnosis
PMF 11
SMF 4
Lille Score at diagnosis of the time of LT
0 4
1 7
2 3
Median time from MF to LT (months) (range) 38 (10-144) (n5 13)
Number of patients with prior splenectomy 5
Prior therapy for myelofibrosis
Hydroxyurea 9
Thalidomide/lenalidomide 4
Interferon 3
Azacitidine/decitabine 2
Anabolic steroids 2
Erythropoietin 1
Bortezomib 1
Number of patients who received cytoreductive
chemotherapy prior to transplant
13
Number of patients with LT in CR at transplant 6
Cytogenetics at LT
Normal 3
CRS 1 abnormalities (+1, 1q-, t(1;6),
der (1;19), t(1;17), dup(1), del(1))
7
CRS 7 abnormalities (del 7, 7q-, t(7;10)) 3
CRS 8 abnormalities (+8, -8, t(3;8)) 4
Complex karyotype 4
PMF indicates primary myelofibrosis; SMF, secondary myelofibrosis; LT,
leukemic transformation; CR, complete remission from acute myeloge-
nous leukemia; CRS, chromosome; MF, myelofibrosis.
Table 2. Transplant Characteristics
Number
Donor
MSD 8
MUD 4
1 antigen mismatched related 2
Cell type
G-CSF mobilized peripheral blood stem cells 10
Bone marrow 4
Conditioning
Reduced-intensity (Melphalan-based)
Melphalan 140 mg/m2 + fludarabine 120 mg/m2 +
Gemtuzumab (2, 4, 6, 9 or 16 mg/m2)
8
Melphalan 100 mg/m2 + fludarabine 120 mg/m2 1
Myeloablative (Busulfan-based) 3
i.v. Busulfan 520 mg/m2 + fludarabine 160 mg/m2 1
i.v. Busulfan 520 mg/m2 + clofarabine 120 mg/m2 +
fludarabine 40 mg/m2
1
p.o. Busulfan 1 mg/kg 10 doses + cyclophosphamide
120 mg/kg + thiotepa 750 mg/m2
GVHD prophylaxis
Tacrolimus + methotrexate 13
Cyclosporine + methotrexate 1
MSD indicates matched sibling donor; MUD, matched unrelated donor;
i.v., intravenous; p.o., oral; GVHD, graft-versus-host disease; G-CSF,
granulocyte colony-stimulating factor.
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plant was 7%, range: 0%-36%), and 1 had progressive
disease (86% blasts) at the time of transplantation.
Three patients had prior autologous (1) or ASCT (2)
for myelofibrosis at different institutions.
Transplantation for acute leukemia was performed
from matched siblings, unrelated or 1 antigen mis-
matched related donors (Table 2). Conditioning
included reduced-intensity conditioning (RIC) pre-
parative regimens in 9 patients using melphalan
(Mel), Flu 6 gemtuzumab ozogamicin, and myeloa-
blative (MA) conditioning using busulfan (Bu)-based
conditioning [9,10]. Although there are limitations to
these terms, the conditioning regimens that included
Bu 520 mg/m2 total dose were considered MA condi-
tioning whereas those including Mel 140 mg/m2 or
less were considered RIC. Antithymocyte globulin
(ATG) was administered to patients who received
a matched unrelated or mismatched related graft.Definitions
Engraftment was defined as achieving an absolute
neutrophil count (ANC) . 0.5  109/L for at least 3
consecutive days before day 30, with donor derived
cells detected by DNA microsatellite analysis. Platelet
recovery was defined as the first day on which the
platelet count was.20 109/L unsupported by plate-let transfusions for 7 days. Acute graft-versus-host dis-
ease (aGVHD) and chronic GVHD (cGVHD) were
defined and graded according to previously described
criteria [11,12].
Statistical Methods
Progression-free survival (PFS) and overall survival
(OS)were estimated by theKaplan-Meiermethod [13].
Days to engraftment for patients with or without sple-
nectomywere compared using theWilcoxon rank-sum
test [14]. The incidence of disease progression, nonre-
lapse mortality (NRM), and GVHD was estimated
using the cumulative incidence method to account for
competing events. Death in the absence of disease pro-
gression, disease progression, and death without
GVHD were considered as competing events for the
respective outcomes. Statistical significance was de-
fined at the .05 level.RESULTS
Transplant outcomes are summarized in Table 2.
Briefly, all patients engrafted after a median of 13
days for neutrophils and 21.5 days for platelets. Of
13 patients who had PB chimerism performed by
PCR on day 30 after transplant, 10 had 100% donor
myeloid and T cells. Three patients had a mixed chi-
merism (90% donor cells) on day 30, subsequently in-
creased to 100% in 2 patients and decreased in 1 who
subsequently relapsed.
Seven patients died after a median follow-up of 1
year, 3 of relapsed disease, 2 of infection, 1 of
GVHD, and 1 secondary to decompensated liver
Table 3. Outcomes of 14 Patients with Myelofibrosis and
Leukemic Transformation Treated with Allogeneic Stem Cell
Transplantation
Primary engraftment (%)* 100%
Engraftment (median, range)
Day to ANC 500 (N5 14) 13 (8-21)
Days to platelet count 20,000 (N5 11) 21.5 (13-40)
Chimerism at day 30 by PCR* (N5 14)
100% 11
85%-99% 2
Not tested 1
Median follow-up survivors, months (range) 31 (10-127)
aGVHD, n
Grade II-IV 5
Grade III-IV 2
cGVHD, n
All grades 5
Extensive 2
Complete remission after transplant, n 14
Disease progression
n (% CI) 4 (38%) (16-89)†
NRM, Overall
n (% CI) 4 (29%) (12-65) †
PFS, Overall
n (% CI) 6 (33%) (7-63) †
OS, Overall
n (% CI) 7 (49%) (22-72) †
ANC indicates absolute neutrophil count; PCR, polymerase chain reac-
tion; aGVHD, acute graft-versus-host-disease; cGVHD, chronic graft-
versus-host disease; NRM, nonrelapse mortality; PFS, progression-free
survival; OS, overall survival; CI, cumulative incidence.
*Donor myeloid and T cells.
†95% Confidence interval.
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low-up for survivors was 31 months (range: 10-127
months). Causes of death included disease relapse in
2 patients and NRM in 3 patients (2 pneumonia and
1 decompensated liver disease) for the patients who re-
ceived Mel-based conditioning, and 1 because of re-
lapse disease and 1 NRM (GVHD) in the Bu-based
conditioning group. OS was 49% at 2 years and at
last follow-up (Figure 1). The cumulative incidence
of NRM was 29% (95% confidence interval [CI] 12-
65) at 2 years and overall.
All patients achieved remission after transplant
while 4 relapsed. One patient relapsed 42 months
after a matched sibling donor transplant and received
a second allogeneic transplant using a 4/6 allele
matched cord blood unit (CBU) added to the sibling
PB stem cells (PBSCs) to augment graft-vesus-tumor
effect, part of a separate clinical trial. The cumulative
incidence of disease progression was 23% (95% CI
9-63) at 2 years and 38% (95% CI 16-89) at last fol-
low-up, whereas PFS was 49% (95% CI 20-70) at 2
years and 33% (95% CI 7-63) at the last follow-up
(Table 3).
Five patients developed grade II-IV aGVHD and 5
patients developed cGVHD (2 de novo, whereas 3 pro-
gressed after aGVHD). The cumulative incidence was
39% (95% CI 19-77) for each event.
JAK2V617F was positive in 6 of 8 tested patients,
with 71% median allele burden (range: 13%-86.7%).
This percentage decreased after induction chemother-
apy to a median of 46% with a wide variation, ranging
from no change in 1 patient (71%), to a 7-fold decrease
in another patient (from 72%–10%). All JAK2V617F-
positive patients became negative on day 30 after trans-
plant. The only 2 patients with JAK2V617F disease
who relapsed were again positive for JAK2V617F.
Cytogenetic abnormalities were present in 11 of 14
patients with LT; clonal evolution occurred in almostFigure 1. OS (continuous line) and DFS (interrupted line) for 14 con-
secutive patients with myelofibrosis and leukemic transformation
treated with ASCT.all these patients at the time of progression to acute
leukemia. Interestingly, 7 of 11 patients (64%) had ab-
normalities of chromosome 1 at the time of LT (Table
1). Three patients with normal cytogenetics did not ac-
quire any cytogenetic abnormalities at the time of
transformation. All JAK2V617F-positive patients
with LT had clonal evolution except 1. Prior splenec-
tomy did not appear to favor the acquisition of new cy-
togenetic abnormalities or hasten progression to LT
(median time to progression 37.5 months in splenec-
tomized patients, n5 4).
It is likely that patients with low disease burden at
transplant do better; however, this could not be
demonstrated by this report; 3 of 6 patients in remission
and 4 of 8 patients with relapsed disease at transplant
survived long term. Two patients with persistent high
tumor burden after induction chemotherapy (.30%
blasts) fared poorly. No other factors associated with
outcomes including conditioning chemotherapy were
identified.DISCUSSION
LT has been reported to occur after a median of 31
months from the diagnosis of myelofibrosis, at a me-
dian age of 66 years [6]. Factors predicting of its devel-
opment were leukocytosis, increase percentage of
blasts in the PB, progressive anemia, or increased num-
ber of karyotypic abnormalities (.2) [15-17].
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sial whether JAK2V617F or allele burden accumulation
is associatedwithLTornot [18,19]. Ina small numberof
patients, wehave found that the allele burdendecreased
with disease progression, suggesting that the evolution
to an accelerated phase may originate in a clone inde-
pendent of the one carrying this mutation [20].
With the available treatment, the median survival
for patients with LT is approximately 3 months
[6,21]. The outcomes of these patients were similar
among those treated with high or low intensity chemo-
therapy, or no treatment at all [6]. Approximately 40%
of patients who received induction chemotherapy for
acute leukemia achieved a temporary remission; how-
ever, this was evidently not enough to obtain long-
term disease control in these patients [6].
Jurado and colleagues [22] previously reported on
a series of 19PVorETpatients (median age of 43 years)
who received an SCT for progression to myelofibrosis,
myelodysplastic syndrome (MDS), or AML. These pa-
tients were treated with MA total body irradiation
(TBI)-based conditioning regimen. All patients trans-
formed to AML except one had a very poor outcome,
predominantly because of a high treatment-related
mortality (TRM) [22]. Improved outcomes for patients
with LT in the present study could be because of, at
least in part, the use of non-TBI, RIC (RIC) for trans-
plantation.
We have previously found that a small number of
patients who received an ASCT after induction che-
motherapy survived long term [20]. Here, we report
the largest experience to date of patients with LT
evolved from myelofibrosis treated with ASCT.
Transplantation was performed mostly from sibling
donors using Flu-Mel-based RIC chemotherapy. Re-
markably, approximately half of these patients
achieved survival and long-term remission of their dis-
ease. The median age was slightly younger than the
median age of patients with LT reported in previous
studies suggesting that at least a subgroup of patients
can be salvaged with transplantation [6]. As expected
in patients with myelofibrosis, all patients with
JAK2V617F-positive LT became negative for this mu-
tation after transplant [23]. This reoccurred in 2 pa-
tients who subsequently relapsed, suggesting that this
mutation could be used to monitor the disease status
after transplant.
In conclusion, this report suggests for the first time
that long-term survival can be achieved in patients with
myelofibrosis and LT. Induction chemotherapy fol-
lowed by transplantation for patients with good per-
formance status and possible low tumor burden may
be required to achieve this goal.
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